BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 963 filers reported holding BAXTER INTL INC in Q2 2023. The put-call ratio across all filers is 0.79 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $448,766 | -10.6% | 9,850 | 0.0% | 0.27% | -24.3% |
| Q4 2022 | $502,055 | -5.5% | 9,850 | 0.0% | 0.36% | -13.2% |
| Q3 2022 | $531,000 | -16.1% | 9,850 | 0.0% | 0.42% | -10.7% |
| Q2 2022 | $633,000 | -25.2% | 9,850 | 0.0% | 0.47% | -7.2% |
| Q4 2021 | $846,000 | +6.8% | 9,850 | 0.0% | 0.50% | -2.9% |
| Q3 2021 | $792,000 | -0.1% | 9,850 | 0.0% | 0.52% | -0.2% |
| Q2 2021 | $793,000 | -4.6% | 9,850 | 0.0% | 0.52% | -10.8% |
| Q1 2021 | $831,000 | +4.9% | 9,850 | 0.0% | 0.58% | -8.1% |
| Q3 2020 | $792,000 | -1.0% | 9,850 | 0.0% | 0.63% | -23.8% |
| Q1 2020 | $800,000 | -2.9% | 9,850 | 0.0% | 0.83% | +16.9% |
| Q4 2019 | $824,000 | -4.4% | 9,850 | 0.0% | 0.71% | -10.7% |
| Q3 2019 | $862,000 | +6.8% | 9,850 | 0.0% | 0.80% | +12.0% |
| Q2 2019 | $807,000 | +0.7% | 9,850 | 0.0% | 0.71% | -1.0% |
| Q1 2019 | $801,000 | +23.6% | 9,850 | 0.0% | 0.72% | +9.1% |
| Q4 2018 | $648,000 | -14.6% | 9,850 | 0.0% | 0.66% | -1.5% |
| Q3 2018 | $759,000 | +4.4% | 9,850 | 0.0% | 0.67% | +0.5% |
| Q2 2018 | $727,000 | +13.4% | 9,850 | 0.0% | 0.66% | +13.7% |
| Q1 2018 | $641,000 | +0.6% | 9,850 | 0.0% | 0.58% | +0.9% |
| Q4 2017 | $637,000 | – | 9,850 | – | 0.58% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |